Related Experiment Video
Updated: Dec 25, 2025

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC Crosslinking of Small Molecules to Isolate Chromatin
Published on: January 20, 2016
Loci specific epigenetic drug sensitivity
Thanutra Zhang1, Anna Pilko1,2, Roy Wollman1,2
1Institute for Quantitative and Computational Biosciences, University of California, Los Angeles, CA, USA.
Abstract:
Therapeutic targeting of epigenetic modulators offers a novel approach to the treatment of multiple diseases. The cellular consequences of chemical compounds that target epigenetic regulators (epi-drugs) are complex. Epi-drugs affect global cellular phenotypes and cause local changes to gene expression due to alteration of a gene chromatin environment. Despite increasing use in the clinic, the mechanisms responsible for cellular changes are unclear. Specifically, to what degree the effects are a result of cell-wide changes or disease related locus specific effects is unknown. Here we developed a platform to systematically and simultaneously investigate the sensitivity of epi-drugs at hundreds of genomic locations by combining DNA barcoding, unique split-pool encoding, and single cell expression measurements. Internal controls are used to isolate locus specific effects separately from any global consequences these drugs have. Using this platform we discovered wide-spread loci specific sensitivities to epi-drugs for three distinct epi-drugs that target histone deacetylase, DNA methylation and bromodomain proteins. By leveraging ENCODE data on chromatin modification, we identified features of chromatin environments that are most likely to be affected by epi-drugs. The measurements of loci specific epi-drugs sensitivities will pave the way to the development of targeted therapy for personalized medicine.
Insights
New platform reveals locus-specific drug sensitivities for epigenetic modulators (epi-drugs). This advances understanding of how epi-drugs affect gene expression, paving the way for targeted therapies.
Area of Science:
- Epigenetics and Genomics
- Chemical Biology
- Drug Discovery
Background:
- Therapeutic targeting of epigenetic modulators (epi-drugs) presents a novel treatment strategy for various diseases.
- The precise mechanisms underlying cellular changes induced by epi-drugs remain unclear, particularly the extent of global versus locus-specific effects.
Purpose of the Study:
- To develop a platform for systematically investigating epi-drug sensitivity at numerous genomic locations.
- To differentiate between cell-wide and disease-related locus-specific effects of epi-drugs.
Main Methods:
- Combined DNA barcoding, unique split-pool encoding, and single-cell expression measurements.
- Integrated internal controls to isolate locus-specific effects from global drug consequences.
- Leveraged ENCODE data on chromatin modification.
Main Results:
- Discovered widespread locus-specific sensitivities to three distinct epi-drugs targeting histone deacetylase, DNA methylation, and bromodomain proteins.
- Identified specific chromatin environment features susceptible to epi-drug action.
- Demonstrated the platform's capability to simultaneously assess hundreds of genomic locations.
Conclusions:
- Locus-specific drug sensitivities are prevalent and predictable based on chromatin features.
- This platform enables precise measurement of epi-drug effects, crucial for developing targeted therapies.
- Findings support the advancement of personalized medicine through tailored epigenetic drug treatments.
Related Concept Videos
Tissue-Drug Binding: Localization of Drugs and its Significance
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Treatment Resistant Cancers

